Novel Systemic Therapies for Small Cell Lung Cancer

Charles M. Rudin, MD, PhD; Christine L. Hann, MD; Craig D. Peacock; and D. Neil Watkins, MBBS, PhD, Baltimore, Maryland

Key Words
Small cell lung cancer, novel therapeutics, Bcl-2, Hedgehog, SVV-001

Abstract
A diagnosis of small cell lung cancer (SCLC) today confers essentially the same terrible prognosis that it did 25 years ago, when common use of cisplatin-based chemotherapy began for this disease. In contrast to past decades of research on many other solid tumors, studies of combination chemotherapy using later generation cytotoxics and targeted kinase inhibitors have not had a significant impact on standard care for SCLC. The past few years have seen suggestions of incrementally improved outcomes using standard cytotoxics, including cisplatin-based combination studies of irinotecan and amphubicin by Japanese research consortia. Confirmatory phase III studies of these agents are ongoing in the United States. Antiangiogenic strategies are also of primary interest and are in late-phase testing. Several novel therapeutics, including high-potency small molecule inhibitors of Bcl-2 and the Hedgehog signaling pathway, have shown remarkable activity against SCLC in preclinical models and are currently in simultaneous phase I clinical development. Novel therapeutic approaches based on advances in understanding of the biology of SCLC have the potential to radically change the outlook for patients with this disease. (JNCCN 2008;6:315–322)

Small Cell Lung Cancer: In Need of New Ideas
Small cell lung cancer (SCLC) is a common and nearly always fatal disease; it represents approximately 15% of all lung cancers, or approximately 26,000 cases annually in the United States. This disease is strongly associated with tobacco exposure and is expected to be an increasingly prevalent concern, particularly in Asia and the developing world, mirroring smoking trends worldwide.

SCLC has a marked predilection for early, distant metastasis; approximately two thirds of SCLC cases are in advanced stage of disease at diagnosis. Patients with advanced-stage SCLC are considered incurable, and with current standard treatment have a median survival time of approximately 9 to 10 months from diagnosis; 5-year survival is exceedingly rare. Limited-stage SCLC, functionally defined as disease confined to 1 hemithorax and which can be encompassed in a single radiation port, also carries a dismal prognosis, with median survival of approximately 18 months from diagnosis. However, in contrast to extensive-stage disease, limited-stage SCLC is potentially curable using current multimodality therapy, with long-term disease-free survival in approximately 20% to 25% of cases.

Standard therapy for advanced- and limited-stage SCLC differs primarily in the addition of concomitant radiation for limited-stage disease. Typical first-line chemotherapy, regardless of stage, consists of a platinum agent (cisplatin or carboplatin) paired with a second agent, in the United States usually the topoisomerase II inhibitor etoposide. This essential treatment paradigm was initiated in the early 1980s and has undergone only minor subsequent modifications, primarily limited to improvements in supportive care medications and in the timing, focus, and intensity of radiation.

Clinical Barriers to Progress in SCLC
The advent of platinum-based chemotherapy caused considerable optimism among lung cancer clinical researchers
about the potential for further rapid progress against SCLC. SCLC, in contrast to non–small cell lung cancer (NSCLC), is a remarkably chemosensitive tumor, with objective response rates of 60% to 80% to standard chemotherapy. Several newer chemotherapeutic agents, including topotecan, paclitaxel, and gemcitabine, were found to have promising activity. However, throughout the 1980s and 1990s, none of the newer agents tested as single agents, as combinations, or added to cisplatin and etoposide seemed to offer any significant improvement over standard therapy. Despite initial chemosensitivity, extensive-stage SCLC recurs universally, and recurrent disease is relatively resistant to further therapy. Attempts at postinduction maintenance chemotherapy have been universally unsuccessful. These failures promoted a climate of nihilism about further clinical investigation in SCLC.

Solid tumor clinical research has focused predominantly on the development and testing of high-potency inhibitors of cell surface receptor tyrosine kinases over the past decade. SCLC, in contrast to NSCLC and several other common solid tumors, does not seem to depend on endothelial growth factor receptor (EGFR) family receptor tyrosine kinases for survival or proliferation. These key oncogenic factors are frequently undetectable in SCLC. Targeted inhibition of c-Kit, an alternative receptor tyrosine kinase that seems to be upregulated in a subset of SCLC, showed no clinical activity in SCLC. The oncogenic factors p53 and Rb, which are most strongly implicated in malignant transformation of SCLC, are not kinases and are notoriously difficult targets for selective pharmacologic intervention.

Preclinical Barriers to Progress in SCLC
A final barrier to progress has been a relative absence of predictive preclinical models of human SCLC. Tobacco smoke–exposed mice do not typically develop lung tumors similar to SCLC. This issue was partially addressed by Meeuwen et al. in 2003 when they showed that targeted somatic inactivation of both p53 and Rb led to development of murine lung neuroendocrine tumors that were phenotypically similar to human SCLC. However, the usefulness of this 2-hit transgenic approach as a therapeutic model is unclear. Clinical SCLC, induced by tobacco carcinogens, is marked by a diversity of genetic alterations, is biologically heterogeneous, and most notably shows severe chromosomal instability. None of these features, which are key contributors to the emergence of therapeutic resistance, are reflected in extant transgenic models of SCLC.

The most common in vivo model for anticancer drug development is based on the use of human cancer cell lines implanted as tumor xenografts in recipient animals. Although it allows response analysis of actual human tumors, this model has clear limitations. Both genetic and epigenetic characteristics of cancer cells are influenced by culture conditions, and these changes may lead to misleading results in preclinical drug studies.

Cancer cell line features that favor preferential selection ex vivo include rapid growth as a monolayer on plastic, growth in fetal calf serum and synthetic media, growth in high pH and glucose conditions, survival through trypsin passaging, and low mutagenicity resulting in a stable and consistent phenotype. Tumor features irrelevant to cell line derivation include angiogenic drive, metastatic potential, and survival in states of hypoxia, nutrient limitation, and high oncotic pressure. Implanted subcutaneously, most standard xenografts grow as localized, noninvasive, nonmetastatic nodules, in marked contrast to human cancers and particularly in contrast to the aggressive behavior of clinical SCLC.

Primary Xenografts: An Emerging Model
The authors’ laboratories have begun to explore an alternative approach to preclinical drug testing in SCLC, using primary xenografts or heterotransplants. This model depends on immediate transfer of human SCLC from patients into recipient mice, without intervening tissue culture or cell line derivation ex vivo. This technique avoids the selective pressures associated with ex vivo cell survival and proliferation through maintaining tumors in a biologically relevant context. Tumors passaged from animal to animal in this model maintain stable histologic and immunophenotypic characteristics. Recent data from several tumor models now suggest that primary xenografting, or xenografting from cells maintained in modified stem cell media, may better maintain the cellular morphology, growth characteristics, chromosome structure, gene copy number, and gene expression of the parental tumor. Taken together, these observations suggest that primary xenograft models may represent a better platform for preclinical therapeutic testing, one that may be more predictive of ultimate clinical efficacy.
Irinotecan and Amrubicin: Renewed Interest in Chemotherapeutics

The topoisomerase I inhibitor topotecan is the only FDA-approved agent for recurrent chemosensitive SCLC, defined as disease that remains stable for 3 months or longer after primary therapy is complete. In this context, topotecan has a response rate of approximately 25% to 30%. In chemorefractory relapse, defined as progressive disease during or within 3 months of completion of primary therapy, topotecan has a response rate of only 2% to 6%. No drugs for relapsed chemorefractory SCLC have been approved by the FDA.

Irinotecan, a topoisomerase I inhibitor closely related to topotecan, has shown promising activity in SCLC. Most notably, a phase III study conducted by the Japanese Clinical Oncology Group (JCOG) comparing cisplatin plus irinotecan with cisplatin plus etoposide in previously untreated advanced SCLC suggested that cisplatin plus irinotecan was a superior first-line regimen, associated with median survival of 12.8 months, compared with 9.4 months for cisplatin/etoposide (P = .002).

Whether the efficacy of irinotecan in Japan will be reflected in similar activity in an American population is unclear. Irinotecan metabolism, tolerance, and efficacy have significant interindividual and interethnic differences, partly attributable to genomic polymorphisms affecting expression of UGT1A1. Two confirmatory phase III studies have been conducted in the United States. The one reported first used a slightly different schedule of cisplatin and irinotecan from that of the JCOG study, and failed to show any improvement in survival relative to cisplatin plus etoposide (P = .74). Survival data for the second study, which precisely mimicked the Japanese dose and schedule, has not yet been reported.

Amrubicin is a synthetic anthracycline, a class of chemotherapeutic agents that, among other mechanisms of action, are potent inhibitors of topoisomerase II. Recent studies from Japan have shown remarkable activity for amrubicin, both as a single agent and in combination with cisplatin. Most impressive has been its reported activity in recurrent, and even chemorefractory, SCLC. Two recent phase II studies reported amrubicin response rates in recurrent SCLC of more than 50%, with one of these studies showing major responses in 8 of 16 patients with chemorefractory SCLC. No phase III studies have been completed involving amrubicin. Nevertheless, these results are highly encouraging and separate confirmatory studies in both chemosensitive and chemorefractory recurrent SCLC are ongoing in the United States.

Antiangiogenic Strategies in SCLC: Starving the Tumor

SCLC is a rapidly growing, highly metabolically active cancer that depends on a rapidly expansive tumor-associated vasculature. High microvessel density and high expression of a key angiogenic mediator, vascular endothelial growth factor (VEGF), are associated with poor outcome in SCLC. Several recently reported studies have tested angiogenic inhibitors in SCLC.

The most extensively studied antiangiogenic agent is the inhibitory VEGF antibody bevacizumab. Preliminary analysis of a phase II study of bevacizumab with first-line cisplatin plus etoposide suggests a response rate of 69% and 6-month survival of 33%. Similar data have been presented as interim reports for bevacizumab with first-line cisplatin plus irinotecan and carboplatin plus irinotecan. Encouragingly, and in contrast to reports in NSCLC, all 3 studies report no grade 3 or higher hemorrhage. Final outcome data from these phase II studies are awaited. A phase III study of the addition of bevacizumab to cisplatin plus etoposide has been initiated.

In addition to antibody-mediated inhibition of the ligand VEGF, several inhibitors of the VEGF receptor (VEGFR) and other angiogenic mediators are in active development. Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor suppressing activity of the key VEGF receptor, VEGFR2. In recent report of a randomized phase II study of vandetanib versus placebo in patients with SCLC after response to primary therapy, the National Cancer Institute of Canada found that vandetanib did not improve overall survival. However, trends were seen toward improved outcome in patients with limited-stage disease but worse outcome in those with extensive-stage disease.

Significant interest has been shown in thalidomide as an antiangiogenic agent that affects multiple vascular proliferative signaling pathways, including suppression of tumor-associated VEGF production. A French consortium recently completed a phase III study of thalidomide versus placebo as maintenance for patients with extensive-stage SCLC after response.
to first-line chemotherapy. No statistically significant difference was seen in overall survival. Benefit seemed to be limited to patients with a lesser performance status (PS 1 or 2), but this is a retrospective exploratory analysis of uncertain significance.

**SCLC and Apoptotic Sensitivity: Bcl-2 as a Target**

Dysregulation of apoptotic signaling pathways is one of the fundamental hallmarks of cancer. Two features of SCLC have made targeting apoptosis in this tumor type a particularly attractive strategy. First, in contrast with most other solid tumors, SCLC shows remarkable sensitivity to multiple apoptotic triggers. The apoptotic threshold of SCLC cell lines to standard cytotoxics is similar to that of many hematologic malignancies; this sensitivity may in part explain the exceptional clinical response rates of SCLC. Second, Bcl-2, a central contributor to the apoptotic dysregulation in SCLC seems to be a well-characterized factor amenable to therapeutic targeting. Bcl-2 is a central apoptotic regulator implicated in cell survival, tumorigenesis, and chemotherapeutic resistance (Figure 1).

Suppression of Bcl-2 levels using an antisense oligonucleotide targeting the bcl-2 mRNA increases the sensitivity of SCLC cell lines and xenografts to standard cytotoxics, including cisplatin and etoposide. Finally, and most notably, targeted inhibition using high-potency, high-specificity, small-molecule inhibitors of Bcl-2 has dramatic single-agent and combinatorial activity against SCLC cell lines treated in vitro and in xenograft models (Christine L. Hann, MD, Personal communication).

Initial clinical translation of these observations, through intravenous administration of a Bcl-2 antisense oligonucleotide, has been disappointing. Oblimersen is a phosphorothioate 18-mer oligonucleotide complementary to the first 6 codons of the bcl-2 mRNA. Two phase I studies and a randomized phase II study have been reported of oblimersen with cytotoxic chemotherapy in patients with SCLC.

The first phase I study combined oblimersen with paclitaxel in patients with chemorefractory relapsed SCLC, based on observations that Bcl-2 and related family members contribute to paclitaxel resistance. Two patients among this cohort with very poor prognosis experienced stable disease, with 1 showing no progression for more than 6 months, but no responses were objective. The second study evaluated oblimersen, carboplatin, and etoposide in patients with newly diagnosed extensive-stage SCLC. This small phase I study reported a promising response rate of 83% (10 of 12 evaluable patients) for the combination, and led directly to a randomized phase II study in the Cancer
and Leukemia Group B consortium comparing carboplatin and etoposide with or without oblimersen. Oblimersen did not improve response rate or survival.\textsuperscript{52,53}

One explanation for the lack of evident enhancement of chemotherapeutic efficacy with oblimersen may be the inadequate intracellular delivery of the oligonucleotide. The authors’ correlational analyses of peripheral blood mononuclear cells of patients receiving oblimersen suggested no consistent effect on Bcl-2 protein level in vivo.\textsuperscript{52} Recent-generation small molecule inhibitors of Bcl-2, in contrast to Bcl-2 antisense oligonucleotides, show a high level of single-agent activity in SCLC xenograft models. These observations caused research in this area to shift from oligonucleotide vectors to small molecule inhibitors.

Clinical studies of at least 3 small molecule inhibitors of Bcl-2 and related Bcl-2 family members in patients with SCLC are either ongoing or will initiate enrollment in the next several months. ABT-263 is an orally bioavailable high-potency Bcl-2/Bcl-xL inhibitor currently being evaluated in a multicenter phase I-II study in patients with recurrent SCLC. Obatoclax and AT-101 are Bcl-2 inhibitors with lower affinity but differing and possibly complementary patterns of selective inhibition across the Bcl-2 family. A 2-institution National Cancer Institute (NCI)-supported phase I-II study is ongoing of obatoclax with topotecan in recurrent, chemosensitive SCLC. An NCI-supported phase II study involving the Mayo and California consortia will evaluate efficacy of AT-101 as a single agent in patients with recurrent SCLC. The outcome of these studies is eagerly awaited.

**SCLC and Embryonic (Stem Cell) Differentiation Pathways: Hedgehog as a Target**

The hedgehog pathway is an essential embryonic signaling cascade that regulates stem/progenitor cell differentiation pathways. It is a critical factor in organismal morphogenesis, including mammalian lung development.\textsuperscript{54,55} Smoothened (Smo) is a transmembrane protein that is absolutely required for activating the downstream hedgehog signaling pathway. Patched, an inhibitory cell surface receptor, constitutively suppresses hedgehog pathway activation through inhibition of Smo. Any of 3 patched ligands (sonic, Indian, and desert hedgehog) can bind to and inactivate patched, derepressing Smo, and promoting pathway activation. Remarkably, evolution from flies to man has not resulted in the development of smoothened paralogs. In contrast, perhaps as many as 7 frizzled receptors exist, which are close relatives of Smo in the Wnt pathway. The discovery that the plant-derived alkaloid cyclopamine is a potent Smo antagonist has propelled efforts to develop high-potency and -specificity hedgehog inhibitors and make Smo one of the most attractive pharmacologic targets for cancer drug discovery.\textsuperscript{56}

The hedgehog pathway has been implicated as a key oncogenic factor for multiple tumor types, which fall into at least 2 fundamentally different classes. One class, including medulloblastoma and basal cell carcinomas, shows inactivating patched mutations, leading to constitutive ligand-independent pathway activation. Preclinical models of tumors with this phenotype are exquisitely sensitive to treatment with Smo inhibitors. A second class, typified by SCLC,\textsuperscript{57} seems to retain pathway integrity but shows ligand-dependent pathway upregulation. Tumors of this class are also inhibited by Smo inhibitors in multiple preclinical models. A high proportion of SCLCs show constitutive ligand-dependent activation of the hedgehog pathway, express high levels of the sonic hedgehog ligand, and are growth-inhibited by Smo inhibitors.\textsuperscript{57,58}

Recent data from several laboratories suggest an unexpectedly close connection in the roles of Hedgehog signaling in regulating normal stem cell differentiation and tumorigenesis.\textsuperscript{59,60} It is becoming increasingly apparent that tumors, in direct analogy with other complex multicellular functional units, comprise large numbers of relatively differentiated cells with limited replicative potential and a very small population of pluripotent progenitors, or cancer stem cells.\textsuperscript{61} In multiple tumor types, the hedgehog pathway seems to be differentially activated within the stem cell compartment. If confirmed, this concept has direct implications for clinical applications of hedgehog pathway inhibitors (Figure 2).

Several pharmaceutical companies are pursuing development of synthetic hedgehog inhibitors. The first agent to be clinically tested is an orally bioavailable inhibitor, GDC-0449, which is currently in a phase I safety and dose-finding study in patients with solid tumors.
SCLC remains almost a universally fatal malignancy, marked by rapid disease recurrence and short survival times. Developments over the past several years suggest a reason for renewed hope in SCLC. Improved in vivo laboratory models of disease, based on transgenic modification of key oncogenic factors leading to murine SCLC and on primary xenografting of human SCLC, have generated new and possibly more predictive platforms for rapidly assessing therapeutic strategies. An improved understanding of the determinants of malignant transformation, clonogenic potential, tumor growth, and metastatic spread has led to the identification of novel targets for drug development in SCLC, several of which are currently being translated into the earliest phases of clinical development. These include concurrent first-in-human, first-in-class phase I studies of a novel anticancer virus with tropism for neuroendocrine tumors, a high-potency Hedgehog pathway inhibitor, and multiple selective Bcl-2 family inhibitors. In the next several years, other targeted therapeutics relevant to SCLC are likely to follow from emerging insights into the SCLC kinome, which is the set of somatically activated kinases characteristic of SCLC. Combinations of these novel therapeutics with the standard regimens, which have been remarkably effective against the bulk of SCLC tumor cells, have the potential to change the prognosis for patients with this disease.

Acknowledgment

Supported by the Burroughs Wellcome Fund and the Flight Attendant Medical Research Institute (CMR).

References

Therapy for Small Cell Lung Cancer


